The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

BMC Cancer
Saber AminChi Lin

Abstract

Immunotherapy has become an essential part of cancer treatment after showing great efficacy in various malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in resectable pancreatic cancer, has not been studied. The primary objective of this study is to compare the OS impact of immunotherapy between PDAC patients who receive neoadjuvant immunotherapy and patients who receive adjuvant immunotherapy. The secondary objective is to investigate the impact of neoadjuvant and adjuvant immunotherapy in combination with chemotherapy and chemoradiation by performing subset analyses of these two groups. Patients diagnosed with PDAC between 2004 and 2016 were identified from the National Cancer Database (NCDB). Multivariable Cox proportional hazard analysis was performed to examine the effect of neoadjuvant and adjuvant immunotherapy in combination with chemotherapy and chemoradiation on the OS of the patients. The multivariable analysis was adjusted for essential factors such as the age at diagnosis, sex, race, education, income, place of living insurance status, hospital type, comorbidity score, and year of diagnosis. Overall, 526 patients received immunotherapy. Among whom, 408/526 (77.57%) rece...Continue Reading

References

Oct 1, 1985·The British Journal of Surgery·T W LennardR M Taylor
Mar 31, 2004·Lancet·Donghui LiJames L Abbruzzese
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gauri R VaradhacharyDouglas B Evans
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas B EvansRobert A Wolff
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele M CorsiniLeonard L Gunderson
Sep 9, 2010·JAMA : the Journal of the American Medical Association·John P NeoptolemosUNKNOWN European Study Group for Pancreatic Cancer
Dec 12, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Jeffrey M HardacreE Gabriela Chiorean
Dec 18, 2012·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Viktor Umansky, Alexandra Sevko
Feb 25, 2014·Journal of the National Cancer Institute·Davendra P S SohalAlok A Khorana
Aug 16, 2014·Cancers·Theerawut ChanmeeNaoki Itano
Aug 26, 2014·World Journal of Gastroenterology : WJG·Nicole E LopezAndrew M Lowy
Dec 3, 2014·Trends in Molecular Medicine·Kim C OhaegbulamXingxing Zang
Mar 22, 2015·Cancer Immunology, Immunotherapy : CII·Laura K AguilarMark Bloomston
Jun 14, 2016·Cell Reports·Katelyn T Byrne, Robert H Vonderheide
Aug 30, 2016·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·S W L de GeusJ F Tseng
Sep 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ali A MokdadPatricio M Polanco
Nov 26, 2016·Cancers·Smitha MenonGrace Dy
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Oct 12, 2017·World Journal of Surgical Oncology·Mashaal DhirChandrakanth Are
Dec 2, 2017·The Surgical Clinics of North America·Robert A Wolff
Mar 23, 2018·Journal of Gastrointestinal Oncology·Ari Rosenberg, Devalingam Mahalingam
Mar 28, 2018·Current Oncology Reports·Marc T Roth, Jordan D Berlin
Apr 17, 2018·The New England Journal of Medicine·Patrick M FordeDrew M Pardoll
Jun 2, 2018·World Journal of Gastroenterology : WJG·Marc HilmiCindy Neuzillet
Jul 13, 2018·JCI Insight·Geoffrey J MarkowitzVivek Mittal
Jul 14, 2018·Annals of Gastroenterological Surgery·Robert J TorphyRichard D Schulick
Oct 17, 2018·Current Opinion in Oncology·Katrien Ghysen, Johan Vansteenkiste
Dec 24, 2018·Therapeutic Advances in Medical Oncology·Kate YoungNaureen Starling
Dec 24, 2018·The New England Journal of Medicine·Thierry ConroyUNKNOWN Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
Jan 5, 2019·Japanese Journal of Clinical Oncology·Fuyuhiko MotoiUNKNOWN Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic
Apr 13, 2019·Translational Gastroenterology and Hepatology·Thomas Seufferlein, Thomas J Ettrich

❮ Previous
Next ❯

Citations

Nov 18, 2020·Cancers·Mithunah KrishnamoorthySaman Maleki Vareki
Feb 25, 2021·International Journal of General Medicine·Yixin XuYulin Tan

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SAS

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.